We are excited to announce a new funding opportunity to provide up to €25,000 EUR ($29,766 USD) to support collaborative research activities between CARRA and PReS early career investigators! The goal is to provide seed funds that allow CARRA and PreS investigators to successfully plan and apply for funds to support larger-scale collaborative research activities. Funds may be used to convene meetings, generate preliminary data and/or to support collaborative pilot studies.
Project submissions are encouraged to leverage infrastructure of CARRA and PReS, address priority research topics for both communities, engage patients and extend expertise that would otherwise not be possible working with either group alone.
Funding Amount: €25,000 EUR ($29,766 USD)
Application Deadline: December 1, 2020
Funding/Project Period: March 1, 2021--February 28, 2022
The first step of CARRA’s newly created Implementation Science Funding Program is the CARRA-Arthritis Foundation Implementation Science Design Grant. This opportunity is intended to support investigator teams at multiple (2-3) sites to conduct Implementation Science Design projects. Through various RFAs the Implementation Science Funding Program aims to support research projects that test strategies designed to improve the implementation of evidence-based practice for the care of patients with pediatric rheumatic conditions in clinical settings.
The CARRA-Arthritis Foundation Implementation Science Design Grant is a collaborative effort by CARRA, the Arthritis Foundation, PR-COIN and the James M Anderson Center for Health Systems Excellence.
Click here for details and eligibility requirements.
Sampath Prahalad’s abstract, “Impact of the Month of Birth on the Development of Juvenile Idiopathic Arthritis in the United States” Was accepted for presentation at the 2020 Pediatric Rheumatology Symposium. Using data from the Legacy and current CARRA Registry, investigators analyzed data from JIA patients and found a link between the development of JIA and birth month. Children with JIA were more likely to be born in January, suggesting that seasonal variations, such as exposure to perinatal infections, may contribute to the development of JIA.
Click here to read the full abstract.
At 201 JDM patients enrolled in the Registry, we have officially crossed the half-way mark to our ultimate goal of 400 patients enrolled. Thank you to everyone for their hard work in helping us reach this milestone! Now is the time to keep the momentum going as we continue to grow the CARRA Registry and move CARRA’s mission forward.
None of this would be possible without our partner, The CureJM Foundation. Their continued financial support has been instrumental in supporting the Registry’s mission. With Cure JM as our partner, we know great things are to come as we work together to better understand, treat, care for, and in the one day, cure juvenile myositis.